Current and future strategies for treating metastatic pancreatic cancer.
Berlin
Jordan D
JD
Gastrointestinal Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, USA.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068818:Cetuximab; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D019468:Disease Management; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005472:Fluorouracil / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; C512478:EGFR protein, human; D066246:ErbB Receptors; C079905:rubitecan; D000068818:Cetuximab; D005472:Fluorouracil; D002166:Camptothecin; D000093542:Gemcitabine